Aurinia Pharmaceuticals Inc (AUPH) - News Archive

The Promising Safety and Efficacy Profile of LUPKYNIS for Lupus Nephritis Revealed at EULAR Congress 2024Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading biopharmaceutical company, recently showcased compelling ne...

Aurinia Pharmaceuticals Inc. recently presented the results of an updated cost-effectiveness analysis of LUPKYNIS (voclosporin), a second-generation calcineurin inhibitor (CNI), during the National Kidney Foundation (NK...

In honor of Lupus Awareness Month, Aurinia Pharmaceuticals is intensifying its efforts to promote awareness and education about the debilitating impact of Lupus Nephritis (LN). Through various initiatives and a comprehe...